Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 600 participants.

Also called NCT03389100

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 2
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03389100
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT03389100. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-07-24 (actual); primary completion 2026-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.
Acronym
NOMEM-Tau
Condition
Diabetes Mellitus, Type 2
Condition
Pre-diabetes
Intervention (Drug)
18F-MK6240 injection
Lead sponsor
Columbia University (class: other)
Collaborator
Hebrew Home at Riverdale (class: other)
Collaborator
National Institute on Aging (NIA) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct03389100
Content hash
017ea7deb428a789ea36755a4c6ca963a1f127a724eb71dda64775ffaffdbdaf